Loading…
No business profile yet.
Size HanchorBio (7827.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $511M, the 438th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$120.00 on 6 Nov 2026.
Growth The operating margin is -225.2% (peer median -3.6%).
Valuation It trades at 2.5× forward earnings against a peer median of 20.9× (cheapest of 7).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$322M | NT$312M | NT$0 | NT$0 | NT$3.36M |
| Revenue growth | — | — | — | -100% | — |
| Gross profit | NT$274M | NT$274M | -NT$37.4M | -NT$33.9M | -NT$24.8M |
| EBITDA | -NT$685M | -NT$330M | -NT$915M | -NT$504M | -NT$485M |
| Net income | -NT$573M | -NT$277M | -NT$1.35B | -NT$591M | -NT$446M |
| Free cash flow | n/a | -NT$336M | -NT$626M | -NT$462M | -NT$405M |
| Capital expenditure | n/a | NT$18.7M | NT$19.0M | NT$23.2M | NT$70.8M |
| Total debt | NT$140M | NT$101M | NT$46.3M | NT$61.0M | NT$45.2M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7827.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -28.4% | -12.3% | 4th lowest of 21 |
| Distance from 52-week high | -35.8% | -42.6% | 7th highest of 21 |
| Operating margin | -225.2% | -3.6% | 4th lowest of 16 |
| Forward P/E | 2.5× | 20.9× | cheapest of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HanchorBio 7827.TW | Taiwan | $511M | n/a | n/a | -225% | 2.5× | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $507M | -11% | -1% | 26% | n/a | n/a | n/a |
| Neurogene NGNE | United States | $506M | -18% | -100% | n/a | n/a | n/a | n/a |
| DiaMedica Therapeutics DMAC | United States | $505M | +48% | n/a | n/a | n/a | n/a | n/a |
| Berry Genomics 000710.SZ | China | $504M | -5% | -2% | -24% | n/a | n/a | n/a |
| Qurient 115180.KS | South Korea | $503M | -59% | -20% | -517% | n/a | n/a | n/a |
| Crescent Biopharma CBIO | United States | $503M | -28% | n/a | -1,418% | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $526M | -25% | +4% | 8% | 22.6× | n/a | n/a |
| Liaoning Dingjide Petrochemical 603255.SS | China | $530M | -15% | +70% | 5% | 19.2× | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $531M | -33% | +2% | 17% | 11.2× | n/a | n/a |
| Valneva VLA.PA | France | $534M | -2% | -27% | -87% | n/a | n/a | n/a |
| Sinotherapeutics 688247.SS | China | $537M | -14% | -17% | 0% | n/a | 31.6% | +7.0% |
| Scinopharm Taiwan 1789.TW | Taiwan | $482M | -1% | -5% | -4% | 43.8× | 15.2% | +0.5% |
| CHO Pharma 6586.TWO | Taiwan | $480M | +57% | -47% | -17,694% | n/a | n/a | n/a |
| Monopar Therapeutics MNPR | United States | $479M | +12% | n/a | n/a | n/a | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $553M | -19% | +6% | -11% | n/a | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $554M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $469M | -13% | n/a | n/a | n/a | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | n/a | 6.0% | -62.3% |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 6.3× | -14.9% | -36.1% |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 187.6× | n/a | n/a |